79
Views
0
CrossRef citations to date
0
Altmetric
Research

Association between medicine Price declaration by pharmaceutical industries and retail prices in Malaysia’s private healthcare sector

, ORCID Icon &
Article: 15 | Received 28 Dec 2018, Accepted 08 Apr 2019, Published online: 28 Nov 2023

References

  • Thomas S, Beh L, Bin NR. Health care delivery in Malaysia: changes, challenges and champions. J Public Health Africa. 2011;2:93–97.
  • Malaysian Investment Development Authority. Medical and healthcare services: Malaysia Investment in the Services Sector. 2017. Available at: http://www.mida.gov.my/home/administrator/system_files/modules/photo/uploads/20170915172756_BOOKLET%2015-MEDICAL%20AND%20HEALTH%20CARE%20SERVICES.pdf. Accessed 10 Feb 2019
  • Ministry of Health Malaysia. Malaysia national health Accounts health expenditure report 1997-2013. Putrajaya; 2015.
  • Ministry of Health Malaysia. Malaysia National Health Accounts: Health expenditure report 1997-2015. Putrajaya; 2015. Available at: http://jknjohor.moh.gov.my/bmv/uploads/penerbitan/MNHA19972015.pdf. Accessed 2 May 2019.
  • Hassali MA, Tan CS, Wong ZY, Saleem F, Alrasheedy AA. Babar Z-U-D. Pharmaceutical pricing in Malaysia. Pharmaceutical prices in the 21st century. Cham: Springer International Publishing; 2015. p. 171–188.
  • Babar ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese A. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007;4:466–475.
  • Hassali MA, Shafie AA, Babar ZUD, Khan TM. A study comparing the retail drug prices between northern Malaysia and Australia. J Pharm Heal Serv Res. 2012;3:103–107.
  • Wiedenmayer K. Access to medicines medicine supply: lessons learnt in Tanzania and Mozambique. Switzerland; 2004. Available at: http://apps.who.int/medicinedocs/documents/s18422en/s18422en.pdf. Accessed 10 Feb 2019
  • Pharmaceutical Services Division. Malaysian National Medicine Policy. 2012; Available at: https://www.pharmacy.gov.my/v2/sites/default/files/document-upload/buku-dunas.pdf Accessed 10 Feb 2019.
  • Morgan SG, Thomson PA, Daw JR, Friesen MK. Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. Health Policy. 2013;112:248–254.
  • Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HGM, Laing R. Differences in external price referencing in Europe-a descriptive overview. Health Policy (New York). 2012;104:50–60.
  • Hinsch M, Kaddar M, Schmitt S. Enhancing medicine price transparency through price information mechanisms. Glob Health. 2014;10:34.
  • Ahmad NS, Islahudin F. Affordability of essential medicine prices in Malaysia’s private health sector. Patient Prefer Adherence. 2018;12:1231–1237.
  • World Health Organization and Health Action International. Medicine prices-a new approach to measurement: World Health Organization and health action international; 2003. Available at: https://apps.who.int/iris/bitstream/handle/10665/67911/WHO_EDM_PAR_2003.2.pdf?sequence=1&isAllowed=y. Accessed 19 Apr 2019.
  • Management Sciences for Health WHO. International drug Price Indicator guide. Cambridge: management sciences for health; 2010.
  • Susanne G, Margaret E, Noguchi Nakae LR. Price, availability and affordability: an international comparison of chronic disease medicines. Cairo; 2006 Available at: http://haiweb.org/wp-content/uploads/2015/08/Price-Availability-Affordability-An-International-Comparison-of-Chronic-Disease-Medicines.pdf. Accessed 2 May 2019.
  • Bangalee V, Suleman F. Evaluating the effect of a proposed logistics fee cap on pharmaceuticals in South Africa - a pre and post analysis. BMC Health Serv Res. 2015;15:522.
  • Nguyen TA, Knight R, Mant A, Cao QM, Brooks G. Medicine pricing policies: lessons from Vietnam. South Med Rev. 2010;3:12–19. .
  • Silivia EM, Schneeweiss S, Thomas S. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21:89–103.
  • Shafie AA, Hassali MA. Price comparison between innovator and generic medicines sold by community pharmacies in the state of Penang, Malaysia. J Generic Med. 2008;6:35–42.
  • Sooksriwong C, Yoongthong W, Suwattanapreeda S, Chanjaruporn F. Medicine prices in Thailand: a result of no medicine pricing policy. vol. 2; 2009. p. 10–14.
  • Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373:240–249.
  • Russo G, McPake B. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings. Health Policy Plan. 2010;25:70–84.
  • World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies. 2015;
  • Preker AS, Attridge JS. Improving access to medicines in developing countries: application of new institutional economics to the analysis of manufacturing and distribution issues. Washington DC; 2005. Available at: https://openknowledge.worldbank.org/bitstream/handle/10986/13668/320380AttridgeImprovingAccessFinal.pdf?sequence=1&isAllowed=y. Accessed 2 May 2019.
  • Malaysia Competition Commission. Market Review on Priority Sector Under Competition Act 2010 Pharmaceutical sector. 2017.
  • Angelino Antonio, Khanh DT, Ha Nguyen, Pham Tuan. Pharmaceutical Industry in Vietnam: Sluggish Sector in a Growing Market. International Journal of Environmental Research and Public Health. 2017;14
  • Dong J, Mirza Z. Supporting the production of pharmaceuticals in Africa. Bull World Health Organ. 2016;94:71–72.